Brain Protein Blocks Alzheimer's Damage in Mice Study

A naturally occurring brain protein may hold the key to protecting millions from Alzheimer's disease and other forms of dementia.

Researchers at Sanford Burnham Prebys discovered that a protein called SORLA acts as a powerful shield against the toxic tau tangles that drive Alzheimer's. Their findings, published July 17, 2026 in Science Advances, reveal how the brain naturally defends itself and offer hope for future treatments.

Alzheimer's disease affects more than 6 million Americans, and tau tangles are one of its most destructive hallmarks. Under healthy conditions, tau proteins support the structure of brain cells. But in Alzheimer's, these proteins twist into toxic clumps that kill neurons and destroy the connections between them.

The research team bred mice with extra SORLA and watched what happened when those animals developed tau tangles. The results were striking. Mice with higher SORLA levels had less brain shrinkage, fewer tau clumps, and healthier connections between neurons.

"When you upregulate SORLA, you can suppress the negative effects found in tauopathies," said lead author Huijie Huang, PhD. "We found there was less brain atrophy and less tau accumulation, which was very exciting to see."

The protective effects worked in multiple ways. SORLA stopped abnormal tau from recruiting more proteins to form larger tangles. It also preserved synaptic plasticity, the brain's ability to form and strengthen connections that underlie memory and learning.

To confirm SORLA's importance, researchers studied mice completely lacking the protein. These animals experienced the opposite outcome. They suffered more severe tau damage, worse brain atrophy, and accelerated decline.

The Bright Side

The discovery opens a clear path toward new therapies. SORLA doesn't just protect neurons directly. It also calms harmful activity in glial cells, the support cells that maintain brain health. When SORLA levels dropped, one specific receptor called plexin-B became overactive in these cells.

That finding matters because drugs already exist that can target plexin-B receptors. "There are unique drugs that can target this class of receptors that we may be able to apply to tau-related dementia disorders," said senior author Timothy Huang, PhD.

The team now plans to test how human brain cells respond to changes in SORLA levels. Their goal is to develop treatments that boost the brain's natural defenses or calm the harmful processes that SORLA normally keeps in check.

For the first time, scientists can see how the brain protects itself from one of Alzheimer's most destructive forces and potentially harness that power to help millions.